MacroGenics closes Phase 2 enoblituzumab study after 7 hemorrhagic fatalities in head and neck cancer

MACROGENICS INC

Phase 2 study CP-MGA271-06 closed due to 7 fatal hemorrhagic events among 62 SCCHN patients.
6 of 7 deaths assessed as unrelated to study treatment; 1 possibly related; incidence exceeded literature rate of 1–3.6%.
Prior enoblituzumab studies in >340 patients had <1% fatal hemorrhage; nonclinical tox showed no coagulopathy.
Company informed FDA and investigators; no new patients enrolled or treated as of July 7, 2022.
Closure does not affect ongoing MGC018 ADC program; internal review and data analysis continue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.